Breast cancer detection Other
Conditions
Interventions
The study involves taking a blood test (approximately one tablespoon of blood) for analysis. Participants will be asked to participate in the study by signing and initialling a consent form. The blood
Sponsors
Swansea Bay University Health Board
Eligibility
Sex/Gender
Female
Age
18 Years to 120 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 years old or over 2. Confirmed histopathological diagnosis of breast cancer OR benign outcome after assessment from specialist breast triple assessment clinic (control group) 3. Willing to provide informed consent for study participation 4. Able and willing to provide blood serum samples
Exclusion criteria
Exclusion criteria: 1. Male sex (majority of patients with breast cancer are female and the study is unlikely to recruit a sufficient number of male patients to provide a representative sample that could be compared between sexes) 2. Under the age of 18 years old 3. Unwilling/unable to consent to trial participation Patients from vulnerable groups (defined as lacking capacity to freely give informed consent) Unwilling/unable to provide blood samples required for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Test sensitivity and specificity measured using outcomes from specialist breast clinics (cancer/normal assessment findings) to train and test a machine learning algorithm at one timepoint | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To determine an association between modes of presentation/symptomatology of breast cancer measured using Raman spectroscopy at one timepoint 2. To determine an association between breast cancer / pre-malignant conditions (DCIS) measured using Raman spectroscopy at one timepoint | — |
Countries
United Kingdom, Wales
Outcome results
None listed